Randomized trial investigates induction therapy combining rituximab and plasma exchange for seropositive generalized myasthenia gravis, suggesting improved outcomes.
To investigate the feasibility, safety and clinical response to combine Rituximab and plasma exchange (PLEX) as induction therapy for patients with seropositive generalized myasthenia gravis (MG).
No takes yet. Share an insight, caveat, or question.
Isasi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: